Serum IGFBP-3 and IGF-I levels were measured by RIA method (Biocode 1014, Biocode 1010, respectively, Liege, Belgium) and results were expressed as nanograms per milliliter.

RESULTS: Plasma IGFBP-3 levels were lowest in patients with bone metastases (P ≤ .043). IGFBP-2 levels were elevated in prostate cancer patients compared with healthy subjects (P ≤ .006). However, ...